

Table S1. Multivariate Cox proportional hazards analysis output.

Covariates	Coefficient	P-value	HR	95% CI	
				Lower	Upper
Biologic					
Adalimumab	Reference	Reference	Reference	Reference	Reference
Etanercept	0.461	< 0.001	1.586	1.341	1.876
Guselkumab	-0.801	0.053	0.449	0.199	1.011
Infliximab	0.278	0.011	1.321	1.065	1.638
Ixekizumab	-0.493	0.035	0.634	0.387	0.965
Secukinumab	-0.094	0.372	0.911	0.741	1.118
Ustekinumab	-0.493	< 0.001	0.611	0.520	0.719
Age	0.002	0.630	1.002	0.995	1.010
Age at Psoriasis Diagnosis	-0.001	0.814	0.999	0.995	1.004
Age at First Biologic	-0.002	0.607	0.998	0.992	1.005
Bio-Naïve	-0.328	< 0.001	0.721	0.637	0.816
Sex (Male)	-0.262	< 0.001	0.769	0.680	0.870
Weight (kg)	0.002	0.015	1.002	1.000	1.003
Concomitant PsA	0.064	0.301	1.066	0.944	1.205
Comorbidities	-0.037	0.734	1.038	0.777	1.195
Concomitant MTX	0.128	0.263	1.136	0.909	1.421
Baseline PASI	0.010	0.025	1.010	1.001	1.019
Baseline DLQI	0.007	0.134	1.007	0.998	1.016

HR, hazard ratio; CI, confidence interval; PsA, psoriatic arthritis; MTX, methotrexate; PASI, Psoriasis Area and Severity Index; DLQI, Dermatology Life Quality Index

Table S2. Detailed results for gradient boosted trees.

Criterion	Value	Standard Deviation
Accuracy	77.5%	±1.0%
Classification Error	22.5%	±1.0%
AUC	85.1%	±0.6%
Precision	84.5%	±1.3%
Recall	80.7%	±2.4%
F Measure	82.5%	±1.1%
Sensitivity	80.7%	±2.4%
Specificity	71.5%	±1.8%

Table S3. Confusion matrix for gradient boosted trees.

	True 'continue'	True 'stopped'	Class 'precision'
Predicted 'continue'	582	302	65.84%
Predicted 'stopped'	232	1262	84.47%
Class 'recall'	71.50%	80.69%	-----